EpiAxis Therapeutics, a University of Canberra spin out company, has expanded its clinical trial program to include two additional recruitment centres for its Phase 1b metastatic breast cancer program.  Those centres are open for patient recruitment at the Southern Medical Day Care Centre in Wollongong and at the Liverpool Cancer Therapy Centre, which is based at Liverpool Hospital.  The principal investigators are Professor Phil Clingan and Dr Eugene Moylan, respectively.

releasedEpiAxis_Phase 1 Update_December 2018_as